Physician profile
Amber Atkinson
NPI 1417309147
$2,510.80
in general payments reported to CMS, 2019-2025
28 companies · $663 in 2025
The $663 reported for 2025 was more than what 78% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $361 · 2022: $292 · 2023: $635 · 2024: $560 · 2025: $663.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,858.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,858.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $719.84 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $301.41 | 2021-2025 | |
| Novo Nordisk INC | $224.11 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $158.22 | 2022-2025 | |
| Vanda Pharmaceuticals INC. | $123.78 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $114.50 | 2021-2023 | Trintellix |
| Abbott Laboratories | $109.12 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $93.29 | 2023-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $90.04 | 2021-2022 | |
| Verona Pharma, INC. | $59.94 | 2025 | Ohtuvayre |
| Lilly USA, LLC | $54.58 | 2021-2025 | Zepbound, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $53.27 | 2023-2025 | |
| Averitas Pharma INC. | $50.38 | 2025 | Qutenza |
| Medtronic, INC. | $41.92 | 2023-2024 | Intellis Adaptivestim |
| Axsome Therapeutics, INC. | $35.55 | 2025 | Auvelity |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $35.15 | 2021-2024 | Vyepti |
| Pfizer INC. | $31.48 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $28.90 | 2021 | |
| Alkermes, INC. | $26.44 | 2023 | Aristada, Lybalvi |
| Phathom Pharmaceuticals, INC. | $24.51 | 2025 | Voquezna |
| Merck Sharp & Dohme LLC | $20.38 | 2023 | Dificid |
| Sumitomo Pharma America, INC. | $18.61 | 2024 | Gemtesa |
| Ironwood Pharmaceuticals, INC | $17.63 | 2023 | Linzess |
| Novartis Pharmaceuticals Corporation | $16.93 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.45 | 2023 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $16.36 | 2022 | |
| Inari Medical, INC. | $14.21 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Exact Sciences Corporation | $13.80 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Atkinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.